| LPF | leukocytosis-promoting factor; leukopenia factor; lipopolysaccharide factor; localized plaque format... |
|---|---|
| MIF | macrophage inhibitory factor; melanocyte[-stimulating hormone]-inhibiting factor; maximum inspirator... |
| MRF | Markov random field; medical record file; melanocyte-[stimulating hormone]-releasing factor; mesence... |
| RF | radial fiber; radio frequency; receptive field; regurgitant fraction; Reitland-Franklin [unit]; rela... |
| CF | 1) Cystic Fibrosis 2) Complement Fixing antibody 3) Conver... |
| complement-fixation reaction | <immunology> Binding of complement as a result of its interaction with immune complexes (the classical pathway) or particular surfaces (alternative pathway). (18 Nov 1997) |
|---|---|
| complement-fixation test | An immunological test for determining the presence of a particular antigen or antibody when one of the two is known to be present, based on the fact that complement is "fixed" in the presence of antigen and its specific antibody. See: Bordet-Gengou phenomenon. (05 Mar 2000) |
| complement fixation tests | Serologic tests based on inactivation of complement by the antigen-antibody complex (stage 1). Binding of free complement can be visualised by addition of a second antigen-antibody system such as red cells and appropriate red cell antibody (haemolysin) requiring complement for its completion (stage 2). Failure of the red cells to lyse indicates that a specific antigen-antibody reaction has taken place in stage 1. If red cells lyse, free complement is present indicating no antigen-antibody reaction occurred in stage 1. (12 Dec 1998) |
| complement-fixing antibody | Antibody that combines with and sensitises antigen leading to the activation of complement, which may result in cell lysis. Synonym: CF antibody, sensitizing substance. (05 Mar 2000) |
| complement haemolytic activity assay | Usual screening assay for complement. Dilutions of the serum to be tested are added to antibody-coated erythrocytes and the percentage of lysis is measured. The values are expressed by ch50, haemolytic complement units per milliliter, which is the dilution of serum required to lyse 50 percent of the erythrocytes in the assay. (12 Dec 1998) |
| complement inactivators | Serum proteins which act at key sites in the complement sequence to modulate or prevent the progression of the reaction. Absence of these factors leads to uncontrolled activation of the complement system with accompanying disease. (12 Dec 1998) |
| complement membrane attack complex | The assembly of complement plasma glycoproteins c5b, c6, c7, c8, and polymeric c9 as a group on biological membranes. The complex forms transmembrane channels which displace lipid molecules and other constituents, thus disrupting the phospholipid bilayer of target cells leading to cell lysis by osmotic leakage. The formation of the membrane attack complex is the terminal step in the complement cascade. (12 Dec 1998) |
| complement pathway, alternative | The complement activation sequence initiated by the activation of complement factor c3, which is triggered by the interaction of microbial polysaccharides and properdin without participation of an antigen-antibody reaction. (12 Dec 1998) |
| complement pathway, classical | The sequential activation of complement, initiated by antigen-antibody complex and the binding of complement factor c1q to the fc region of the antibody. (12 Dec 1998) |
| complement system | A group of more than 20 serum proteins, some of which can be serially activated and participate in a cascade resulting in cell lysis. (05 Mar 2000) |
| complement unit | The smallest amount (highest dilution) of complement that will cause haemolysis of a unit of red blood cells in the presence of a haemolysin unit. Synonym: alexin unit. (05 Mar 2000) |
| component of complement | Any one of the nine distinct protein units (designated C1 through C9 and distributed in the a, b, and g electrophoretic partitions of normal serum) that effect the immunological activities long associated with complement. C1 is a complex of three subunits: C1q, C1r, and C1s. C1q (overbar indicates "active form") activates proenzyme C1r to C1r which activates C1s to C1s (also known as C1 esterase), which converts proenzyme C2 to C2b and produces C4b from C4. C2b combines with C4b to form "classical-complement-pathway C3/C5 convertase" (also known as C3 convertase, C5 convertase, and C42). This enzyme cleaves C3 to C3a and C3b, and C5 to yield C5a and C5b, as does "alternative-complement-pathway C3/C5 convertase" (also known as proenzyme factor B, properdin factor B, C3 proactivator, and heat-labile factor). Complement factor I (also known as C3b or C3b/C4b inactivator) inactivates C3b and C4b by a different proteolytic cleavage. Several autosomal recessive disorders have been identified in which one or more of the complement components have been deficient or completely absent. (05 Mar 2000) |
| heparin complement | The protein component of heparin in blood. (05 Mar 2000) |
| accelerator factor | <chemical> Heat- and storage-labile plasma glycoprotein which accelerates the conversion of prothrombin to thrombin in blood coagulation. Factor v accomplishes this by forming a complex with factor xa, phospholipid, and calcium (prothrombinase complex). Deficiency of factor v leads to owren's disease. Chemical name: Blood-coagulation factor V (12 Dec 1998) |
| acetate replacement factor | <biochemistry> 1,2 dithiolane 3 valeric acid. Regarded as a coenzyme in the oxoglutarate dehydrogenase complex of the citric acid cycle. Involved generally in oxidative decarboxylations of _ keto acids. A growth factor for some organisms. (18 Nov 1997) |